Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial

BACKGROUND: Asthma treatment guidelines recommend increasing corticosteroid dose to control symptoms and reduce exacerbations. This approach is potentially flawed because symptomatic asthma can occur without corticosteroid responsive type-2 (T2)-driven eosinophilic inflammation, and inappropriately...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lancet Respir Med
Autori principali: Heaney, Liam G, Busby, John, Hanratty, Catherine E, Djukanovic, Ratko, Woodcock, Ashley, Walker, Samantha M, Hardman, Timothy C, Arron, Joseph R, Choy, David F, Bradding, Peter, Brightling, Christopher E, Chaudhuri, Rekha, Cowan, Douglas C, Mansur, Adel H, Fowler, Stephen J, Niven, Robert M, Howarth, Peter H, Lordan, James L, Menzies-Gow, Andrew, Harrison, Tim W, Robinson, Douglas S, Holweg, Cecile T J, Matthews, John G, Pavord, Ian D
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2021
Soggetti:
Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7783382/
https://ncbi.nlm.nih.gov/pubmed/32916135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2213-2600(20)30397-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi